Evidence for a Cyanine Link Between Propargylamine Drugs and Monoamine Oxidase Clarifies the Inactivation Mechanism
Successful propargylamine drugs such as deprenyl inactivate monoamine oxidase (MAO), a target in multi-faceted approaches to prevent neurodegeneration in the aging population, but the chemical structure and mechanism of the irreversible inhibition are still debated. We characterized the covalent cya...
Main Authors: | Alen Albreht, Irena Vovk, Janez Mavri, Jose Marco-Contelles, Rona R. Ramsay |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-05-01
|
Series: | Frontiers in Chemistry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fchem.2018.00169/full |
Similar Items
-
Computational Insights into β-Carboline Inhibition of Monoamine Oxidase A
by: Alja Prah, et al.
Published: (2022-10-01) -
Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors
by: Tapan Behl, et al.
Published: (2021-06-01) -
Hospitalized Patients' Perceived Knowledge and Risk of Monoamine Oxidase Inhibitor Medications Before and After a Pharmacist's Classroom-Based Education
by: Richard G. Wenzel, et al.
Published: (2010-06-01) -
Monoamine Oxidase-B Inhibitor Reduction in Pro-Inflammatory Cytokines Mediated by Inhibition of cAMP-PKA/EPAC Signaling
by: Edward E. Putnins, et al.
Published: (2021-11-01) -
Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies
by: Makoto Naoi, et al.
Published: (2022-09-01)